论文部分内容阅读
目的:探讨血管紧张素Ⅱ受体拮抗药厄贝沙坦对2型糖尿病(T2DM)患者胰岛β细胞功能的影响。方法:80名T2DM患者随机分为观察组和对照组,两组均予门冬胰岛素30注射液控制血糖,观察组在此基础上加用厄贝沙坦片300 mg,po qd,治疗12周。观察比较两组患者治疗前后血糖控制情况,胰岛素抵抗指数(HOMAIR)、细胞功能指数(HOMA-β)及胰岛素分泌指数。结果:治疗前,两组各项指标水平比较,差异均无统计学意义(P>0.05)。治疗后,两组FPG、PPG、HbA1c均较治疗前明显下降(P<0.05),但两组治疗后血糖水平差异无统计学意义(P>0.05)。治疗后,两组HOMA-IR、HOMA-β、ΔC30/ΔG30、ΔC120/ΔG120等指标均较治疗前明显改善(P<0.05);且观察组较对照组改善更明显(P<0.05)。结论:厄贝沙坦联合胰岛素治疗T2DM能显著改善胰岛β细胞功能。
Objective: To investigate the effect of irbesartan, an angiotensin Ⅱ receptor antagonist, on pancreatic β-cell function in patients with type 2 diabetes mellitus (T2DM). Methods: Eighty T2DM patients were randomly divided into observation group and control group. Both groups were given insulin aspart 30 injection to control blood glucose. On the basis of this observation, irbesartan 300 mg and po qd . The blood glucose control, insulin resistance index (HOMAIR), cell function index (HOMA-β) and insulin secretion index were observed and compared between the two groups before and after treatment. Results: Before treatment, there was no significant difference in each index between the two groups (P> 0.05). After treatment, the levels of FPG, PPG and HbA1c in both groups were significantly lower than those before treatment (P <0.05). However, there was no significant difference in blood glucose level between the two groups after treatment (P> 0.05). After treatment, the indexes of HOMA-IR, HOMA-β, ΔC30 / ΔG30 and ΔC120 / ΔG120 in both groups were significantly improved compared with those before treatment (P <0.05); and the observation group improved more significantly than the control group (P <0.05). Conclusion: Irbesartan combined with insulin treatment of T2DM can significantly improve pancreatic β-cell function.